Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870689 | 0.86 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL3888021 | 0.81 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL4959967 | 0.78 | ESR2 (0.46) | MAPK1GPR119 | |
| SCHEMBL5870649 | 0.77 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3OPRK1ALDH1A1 | |
| SCHEMBL5870646 | 0.77 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3OPRK1ALDH1A1 | |
| SCHEMBL5870725 | 0.73 | CHRM2 (0.49) | CHRM2CHRM1CHRM3HSD11B1OPRK1 | |
| SCHEMBL6943848 | 0.72 | PPARG (0.43) | CHRM1ALDH1A1 | |
| SCHEMBL24208627 | 0.71 | CHRM2 (0.53) | CHRM2CHRM1CHRM3HSD11B1ALDH1A1 | |
| SCHEMBL30777200 | 0.71 | CHRM2 (0.53) | CHRM2CHRM1CHRM3HSD11B1ALDH1A1 | |
| SCHEMBL12094583 | 0.71 | GPR119 (0.46) | CHRM2CHRM1CHRM3HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194790-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | GONG LEYI | 2006-08-31 | — | — | US | disclosed |
| US-20060189596-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | GONG LEYI | 2006-08-24 | — | — | US | disclosed |
| US-7081531-B2 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2006-07-25 | — | — | US | disclosed |
| EP-1599472-A1 | CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076448-A1 | CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-10 | — | — | WO | disclosed |
| US-20040176416-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | ROCHE PALO ALTO LLC | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189596-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | CCR3, CCR10, CCR1 | CHRM2 207/4885CHRM1 177/4885CHRM3 40/4885 |
| US-20040176416-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | CCR3, CCR1, CCR10 | CHRM2 155/4885CHRM1 134/4885CHRM3 18/4885 |
| US-20060194790-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | CCR3, CCR10, CCR1 | CHRM2 83/4885CHRM1 61/4885CHRM3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.